PDCD1 and cancer: Since TIM-3, PD-1, and NKG2A are druggable checkpoint molecules that have been shown to harness NK and T cell immune responses in cancer it may be envisaged to use checkpoint inhibitors to unleash their antiviral activity.34 This should be carefully planned and controlled to avoid worsening of the hyperinflammatory state typical of severe COVID-19.